Cargando…
Strong ubiquitous micro-promoters for recombinant adeno-associated viral vectors
Significant progress has been made in developing recombinant adeno-associated virus (rAAV) for clinical gene therapy. While rAAV is a versatile gene delivery platform, its packaging limit of 4.7 kb limits the diseases it can target. Here, we report two unusually small promoters that enable the expre...
Autores principales: | Chai, Sunghee, Wakefield, Leslie, Norgard, Mason, Li, Bin, Enicks, David, Marks, Daniel L., Grompe, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241652/ https://www.ncbi.nlm.nih.gov/pubmed/37287749 http://dx.doi.org/10.1016/j.omtm.2023.05.013 |
Ejemplares similares
-
Production and Titering of Recombinant Adeno-associated Viral Vectors
por: McClure, Christina, et al.
Publicado: (2011) -
Manufacturing of recombinant adeno-associated viral vectors for clinical trials
por: Clément, Nathalie, et al.
Publicado: (2016) -
Manufacturing of recombinant adeno-associated viral vectors: new technologies are welcome
por: Ayuso, Eduard
Publicado: (2016) -
Transduction of ovarian cancer cells: a recombinant adeno-associated viral vector compared to an adenoviral vector
por: Vermeij, J, et al.
Publicado: (2001) -
Adeno-Associated Viral Vectors in Neuroscience Research
por: Haggerty, David L., et al.
Publicado: (2019)